Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes

التفاصيل البيبلوغرافية
العنوان: Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes
المؤلفون: Peter J. Rossi, Martin G. Sanda, Tiffany M. Morgan, Zhengjia Chen, Jaymin Jhaveri, Patrick K. Cutrell, Sara Rahnema, Chao Zhang, Robert H. Press, John G. Pattaras, Ashesh B. Jani, Pretesh Patel
المصدر: Journal of Contemporary Brachytherapy
سنة النشر: 2018
مصطلحات موضوعية: medicine.medical_specialty, medicine.medical_treatment, Brachytherapy, brachytherapy, Urology, HDR, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Quality of life, Prostate, American Urological Association Symptom Score, medicine, Radiology, Nuclear Medicine and imaging, Dosing, Original Paper, business.industry, medicine.disease, prostate cancer, medicine.anatomical_structure, Oncology, quality of life, 030220 oncology & carcinogenesis, Adenocarcinoma, Sexual function, business, boost
الوصف: Purpose There is limited data to support the use of hypofractionated external beam radiation (HypoF) in combination with high-dose-rate brachytherapy (HDR). We report our quality of life (QOL) outcomes when treating intermediate and high-risk prostate cancer patients with external beam radiation (EBRT) plus HDR. Material and methods The charts of 54 patients with localized adenocarcinoma of the prostate treated with standard fractionation (SF) or HypoF EBRT plus HDR boost at a single institution between 2012 and 2015 were reviewed. All patients completed the American Urological Association Symptom Score (AUASS) and Expanded Prostate Index for Prostate Cancer - Clinical Practice (EPIC-CP) quality of life assessments prior to treatment and completed at least one follow-up survey. Linear mixed models were performed to test for significant changes and differences in each outcome over time. Results There was no significant difference in AUA score (p = 0.98), incontinence (urge) and urinary irritation/obstruction scores (p = 0.81 and p = 0.62, respectively), and bowel QOL (p = 0.97) between the two dosing groups over time or at any discrete time point. For both groups, AUA scores peaked at 0-2 months before improving. Likewise, sexual function, vitality score, and QOL scores were also not significantly different between the dose groups over time (p = 0.59, p = 0.37, and p = 0.71, respectively). All QOL categories, except sexual function, trended toward baseline with increasing time from intervention. Conclusions Our study suggests HypoF EBRT can be delivered in combination with HDR for patients with ntermediate-risk and high-risk adenocarcinoma of the prostate without increasing toxicity compared to SF with an HDR boost.
تدمد: 1689-832X
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258332fe5f1dd058128f62ec3e91d3e2
https://pubmed.ncbi.nlm.nih.gov/30038640
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....258332fe5f1dd058128f62ec3e91d3e2
قاعدة البيانات: OpenAIRE